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Effects of a high-dose 24-h infusion of tranexamic acid on 
death and thromboembolic events in patients with acute 
gastrointestinal bleeding (HALT-IT): an international 
randomised, double-blind, placebo-controlled trial
The HALT-IT Trial Collaborators*
Summary
Background Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. 
Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We 
aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. 
Methods We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. 
Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the 
minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and 
had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were 
randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical 
apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 
100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a 
maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h 
for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to 
allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients 
who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. 
This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.
Findings Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid 
(5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated 
treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the 
tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). 
Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and 
placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein 
thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 
5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). 
Interpretation We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our 
results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a 
randomised trial.
Funding UK National Institute for Health Research Health Technology Assessment Programme.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
Acute severe gastrointestinal bleeding is a common 
cause of death worldwide.1 Bleeding can occur from 
the upper or lower gastrointestinal tract, but upper 
gastrointestinal bleeding is more common. The leading 
causes are peptic ulcer, oesophageal varices, and malig­
nancy. The case fatality rate is approximately 10% for 
upper gastrointestinal bleeding and 3% for lower 
gastrointestinal bleeding.2,3 Many patients re­bleed after 
initial haemostasis and those that do have a four­times 
increased risk of death.4 Patients with acute severe gastro­
intestinal bleeding usually present with haematemesis or 
melaena. Patients are often haemodynamically unstable 
and in need of urgent resuscitation. Acute management 
of gastrointestinal bleeding includes blood product 
transfusion, medical or endoscopic therapy, and surgery.
Tranexamic acid reduces bleeding by inhibiting blood 
clot breakdown (fibrinolysis). Tranexamic acid decreases 
surgical bleeding and reduces death due to bleeding in 
patients with traumatic and postpartum haemorrhage.5–8 A 
systematic review and meta­analysis of randomised trials 
of tranexamic acid for upper gastrointestinal bleeding 
included seven trials with a total of 1654 patients.9 There 
was a large reduction in all­cause mortality with tranexamic 
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acid (risk ratio [RR] 0·61, 95% CI 0·42–0·89; p=0·01). 
However, meta­analyses of small trials are prone to 
publication and other selection biases, and have a low 
positive predictive value when compared with results from 
large multicentre trials.10 Furthermore, even in aggregate, 
the trials included in the meta­analysis were too small to 
assess the effect of tranexamic acid on thromboembolic 
adverse events.9 Our objective was to quantify the effects of 
tranexamic acid on death and thromboembolic events in 
acute gastrointestinal bleeding.
Methods
Study design and participants
The HALT­IT trial is an international, randomised, 
double blind (participants and trial staff), placebo­
controlled trial done in 164 hospitals in 15 countries 
(UK, Pakistan, Nigeria, Egypt, Malaysia, Georgia, 
Romania, Nepal, Sudan, Saudi Arabia, Spain, Ireland, 
Albania, Papua New Guinea, and Australia).11 Patients 
were enrolled if they were aged above the minimum 
age considered an adult in their country (either aged 
16 years and older or aged 18 years and older) and if 
the respon sible clinician was substantially uncertain 
whether to use tranexamic acid. The diagnosis of 
significant bleeding was clinical and significant was 
defined as a risk of bleeding to death and included 
patients with hypotension, tachycardia, or signs of 
shock, or those likely to need transfusion or urgent 
endoscopy or surgery.
Severe gastrointestinal bleeding is a frightening 
experience and blood loss can impact on a patient’s 
mental and emotional state, impairing their decision 
making—the consent procedures considered this, as 
well as the need to treat urgently. If the patient was fully 
competent, written consent was sought. If capacity 
was impaired and a personal or professional represen­
tative was available, consent was sought from the 
representative. If neither were able to provide consent, 
it was waived and the patient was informed about 
the trial and consented for ongoing data collection as 
soon as possible afterwards. The trial was approved by 
the UK NRES Committee East of England (reference 
number 12/EE/0038), and by the national and local 
research ethics committees in all participating non­UK 
countries.
Research in context
Evidence before this study
Before this study a Cochrane systematic review and meta-
analysis of randomised trials of tranexamic acid for upper 
gastrointestinal bleeding included seven trials with a total of 
1654 patients. There was a large reduction in mortality with 
tranexamic acid (pooled risk ratio [RR]  0·61, 95% CI 0·42–0·89; 
p=0·01). However, given the small size of the included trials and 
the potential for selection and other biases, we considered this 
evidence to be hypothesis generating, requiring confirmation 
in larger trials. Furthermore, there was substantial uncertainty 
about the risk of thromboembolic events with tranexamic acid 
(pooled RR 1·86, 95% CI 0·66–5·24).
Added value of this study
The HALT-IT trial included 12 009 patients from 164 hospitals 
in 15 countries. Adult patients with significant upper or lower 
gastrointestinal bleeding were randomly assigned to receive 
tranexamic acid (1 g loading dose followed by 3 g maintenance 
dose over 24 h) or matching placebo. Tranexamic acid did not 
reduce death from gastrointestinal bleeding (RR 0·99, 95% CI 
0·82–1·18) but was associated with an increased risk of venous 
thromboembolic events (1·85, 1·15–2·98) and seizures (1·73, 
1·03–2·93).
 Implications of all the available evidence
The most recent update of the Cochrane review included eight 
small randomised trials with 1701 participants and showed a 
reduction in mortality with tranexamic acid (RR 0·60, 95% CI 
0·42–0·87). Although we cannot entirely rule out a modest 
increase or decrease in death due to bleeding with tranexamic 
acid, we can rule out the large mortality reduction suggested by 
the Cochrane review. Furthermore, tranexamic acid appears to 
increase the risk of venous thromboembolic events in patients 
with gastrointestinal bleeding. On the basis of our results, 
tranexamic acid should not be used for the treatment of 
gastrointestinal bleeding outside the context of a randomised 
trial. Our results highlight the unreliability of meta-analyses of 
small trials.
Figure 1: Trial profile
6015 assigned to placebo and baseline 
data collected
5988 received loading dose
5510 received maintenance dose
23 received neither dose
6004 with outcome data
5981 received allocated treatment and 
included in the primary analysis
 
11 consent withdrawn and outcome 
data unavailable
12 009 patients randomly assigned
 
5994 assigned to tranexamic acid and 
baseline data collected
5964 received loading dose
5483 received maintenance dose
29 received neither dose
5985 with outcome data
5956 received allocated treatment and 
included in the primary analysis
6 consent withdrawn and outcome 
data unavailable
3 lost to follow-up
 
7 consent withdrawn but outcome 
data provided 
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Randomisation and masking
An independent statistician from Sealed Envelope (London, 
UK) generated randomisation numbers and these were 
given to Sharp Clinical Services UK (Crickhowell, UK), a 
Good Manufacturing Practice certified clinical trial service 
provider, to make treatment packs. When a patient was 
enrolled, the lowest numbered treatment pack was taken 
from a box of eight packs. Sharp Clinical Services was 
responsible for masking, which involved removing the 
manufacturer’s label and replacing it with the clinical 
trial label and randomisation number. Apart from the 
randomisation number, the pack label text was identical 
for tranexamic acid and placebo. Patients, caregivers, 
and those assessing outcomes were masked to allo­
cation. We checked the coding by testing each batch of 
ampoules with high­performance liquid chromatography 
to determine the contents. Block randomisation was 
used but randomisation was not stratified.
Procedures
Eligible patients were randomly assigned to get 
tranexamic acid or placebo as soon as possible and 
treatment was started immediately. A loading dose of 1 g 
tranexamic acid or placebo (sodium chloride 0·9%) was 
added to a 100 mL infusion bag of 0·9% sodium chloride 
and infused by slow intravenous injection over 10 min, 
followed by a maintenance dose of 3 g tranexamic acid or 
placebo added to 1 L of any isotonic intravenous solution 
and infused at 125 mg/h for 24 h. Every patient was 
assigned a uniquely numbered treatment pack, which 
contained eight ampoules of tranexamic acid 500 mg or 
placebo, one 100 mL bag of 0·9% sodium chloride (to use 
with the loading dose), two sterile 10 mL syringes and 
needles, stickers with the trial details and randomisation 
number (for attaching to infusion bags, forms, and the 
medical records), and instructions. Pfizer, Sandwich, UK 
(PL 00057/0952) manufactured the tranexamic acid 
Tranexamic acid 
(n=5994)
Placebo 
(n=6015)
Age at randomisation, years
Mean (SD) 58·1 (17·0) 58·1 (17·0)
<40 791 (13%) 779 (13%)
40–59 2356 (39%) 2333 (39%)
60–79 2078 (35%) 2130 (35%)
≥80 769 (13%) 773 (13%)
Sex
Female 2142 (36%) 2124 (35%)
Male 3852 (64%) 3891 (65%)
Time from onset to randomisation, h
Mean (SD) 21·4 (36·4) 22·5 (37·8)
≤3 960 (16%) 975 (16%)
>3–≤8 1607 (27%) 1551 (26%)
>8 3427 (57%) 3488 (58%)
Missing 0 1 (<1%)
Suspected location of bleeding
Lower 674 (11%) 654 (11%)
Upper 5320 (89%) 5361 (89%)
Haematemesis
Yes 4285 (72%) 4240 (71%)
No 1709 (29%) 1775 (30%)
Melaena or fresh blood per rectum
Yes 4573 (76%) 4626 (77%)
No 1421 (24%) 1389 (23%)
Suspected variceal bleeding
Yes 2694 (45%) 2739 (46%)
No 3300 (55%) 3276 (54%)
Suspected active bleeding
Yes 5247 (88%) 5226 (87%)
No 747 (12%) 789 (13%)
Systolic blood pressure, mm Hg
≥90 5222 (87%) 5216 (87%)
76–89 577 (10%) 577 (10%)
≤75 181 (3%) 201 (3%)
Missing 14 (<1%) 21 (<1%)
(Table 1 continues in next column)
Tranexamic acid 
(n=5994)
Placebo 
(n=6015)
(Continued from previous column)
Heart rate, beats per min
<77 812 (14%) 756 (13%)
77–91 1546 (26%) 1644 (27%)
92–107 1760 (29%) 1720 (29%)
>107 1864 (31%) 1885 (31%)
Missing 12 (<1%) 10 (<1%)
Signs of shock
Yes 2574 (43%) 2648 (44%)
No 3420 (57%) 3367 (56%)
Rockall score
1–2 1419 (24%) 1395 (23%)
3–4 2306 (38%) 2332 (39%)
5–7 2269 (38%) 2288 (38%)
Taking anticoagulants
Yes 528 (9%) 500 (8%)
No 5422 (90%) 5466 (91%)
Unknown 44 (1%) 49 (1%)
Emergency admission
Yes 5673 (95%) 5687 (94%)
No 321 (5%) 328 (6%)
Major comorbidities
Cardiovascular 1108 (18%) 1132 (19%)
Respiratory 337 (6%) 324 (5%)
Liver 2432 (41%) 2532 (42%)
Renal 325 (5%) 310 (5%)
Malignancy 417 (7%) 382 (6%)
Other 999 (17%) 968 (16%)
Any comorbidity 4308 (72%) 4329 (72%)
Data are n (%) or mean (SD).
Table 1: Baseline characteristics
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and Torbay and South Devon NHS Foundation Trust 
(MIA [IMP] 13079) manufactured the sodium chloride 
0·9% placebo. We provided information for patients 
and representatives, consent forms, and data collection 
forms. Stickers, instructions, leaflets, and forms were in 
local languages.
Once randomly assigned, we collected outcome data 
even if the treatment was not given. Outcome data 
were collected at death, discharge from the randomising 
hospital, or 28 days after randomisation, whichever 
occurred first. Trial investigators and their institutions 
provided direct access to the source data for trial­related 
monitoring, audits, and regulatory inspections. Moni­
toring was done according to the Sponsor’s Standard 
Operating Procedure and the trial protocol. Formal 
inspections were carried out by the relevant Regulatory 
Agencies including the UK Medicines and Healthcare 
products Regulatory Agency, Irish Health Products 
Regulatory Authority, and Nigeria’s National Agency for 
Food and Drug Administration and Control. Adherence to 
allocation sequence was monitored throughout the trial 
and any out of sequence pack use was automatically 
flagged in the trial database and the investigators were 
retrained.
Outcomes
The primary outcome was death due to bleeding within 
5 days of randomisation. Cause of death was assigned by 
local principal investigators who provided a narrative of 
events leading to death. These were reviewed by the chief 
investigator (masked to treatment allocation) and queried 
if more information was needed to confirm whether death 
was due to bleeding or another cause. Secondary outcomes 
were death due to bleeding within 24 h and within 28 days 
of randomisation, all­cause and cause­specific mortality 
at 28 days, rebleeding within 24 h, within 5 days, and 
within 28 days of randomisation, surgery or radiological 
intervention, blood product trans fusion, thromboembolic 
events (deep vein thrombosis, pulmonary embolism, 
stroke, and myocardial infarction), seizures, other com­
plications (including other significant cardiac event, 
sepsis, pneumonia, respiratory failure, renal failure, liver 
failure), days in an intensive care unit, and functional 
status. The diagnosis of rebleeding was made by the 
clinician based on established criteria. A diagnosis of 
thromboembolic events was made using strict definitions 
and diagnostic criteria, including a clinical assessment, 
diagnostic imaging, biomarker tests, and post­mortem 
examination. Seizures were diagnosed by clinical assess­
ment. Functional status was measured with the Katz 
Index of Independence in Activities of Daily Living either 
at hospital discharge or in­hospital at 28 days.
Statistical analysis
The sample size calculation was initially based on all­
cause mortality as the primary outcome since we expected 
that most deaths would be due to bleeding.11 However, 
while the trial was underway, we observed that over half of 
all deaths were due to non­bleeding causes. Accumulating 
evidence from other large trials of tranexamic acid showed 
no apparent effect on non­bleeding deaths.12 Furthermore, 
patients received tranexamic acid (or placebo) only for 
their initial bleed and because tranexamic acid has a short 
half­life (approximately 2 h), it will be largely eliminated 
within 2 days. As such, we did not expect tranexamic acid 
to reduce deaths from rebleeding episodes many weeks 
after randomisation. The primary outcome was therefore 
changed to death due to bleeding within 5 days of 
randomisation on Nov 21, 2018. Based on the amended 
primary outcome, assuming a risk of death due to 
bleeding of 4%, a study with 12 000 patients has about 
85% power (two­sided α of 5%) to detect a clinically 
important 25% relative reduction in death due to bleeding 
from 4% to 3%.
We published the statistical analysis plan before 
unblinding.13 The plan gave our reasons for amending 
the primary outcome measure and for increasing 
the sample size. The main analyses compared those 
allocated tranexamic acid with those allocated to placebo 
Figure 2: Mortality by days from randomisation
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Tranexamic acid 
(n=5956)
Placebo
(n=5981)
Risk ratio
(95% CI)
Death due to bleeding within 24 h 124 (2·1%) 120 (2·0%) 1·04 (0·81–1·33)
Death due to bleeding within 5 days 222 (3·7%) 226 (3·8%) 0·99 (0·82–1·18)
Death due to bleeding within 28 days 253 (4·2%) 262 (4·4%) 0·97 (0·82–1·15)
Rebleeding within 24 h* 41 (0·7%) 41 (0·7%) 1·00 (0·65–1·55)
Rebleeding within 5 days* 287 (4·8%) 315 (5·3%) 0·91 (0·78–1·07)
Rebleeding within 28 days* 410 (6·8%) 448 (7·5%) 0·92 (0·81–1·05)
Data are n (%) and risk ratio (95% CI). Death or rebleeding in hospital during follow-up. *Excludes 13 patients missing 
data on rebleed status or rebleed date.
Table 2: Effect of tranexamic acid on death due to bleeding and rebleeding
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on a modified intention­to­treat basis, excluding patients 
who received neither dose of the allocated treatment and 
those for whom outcome data on death were unavailable. 
We present effect estimates (RRs) with a measure of 
precision (95% CI). The safety of partici pants was over­
seen by an independent data monitoring committee, 
which reviewed four non­masked interim analyses. 
We planned to report four subgroup analyses to examine 
the effects of tranexamic acid on the primary outcome 
stratified by the following baseline characteristics: 
time to treatment (≤3 h, >3 h), site of bleeding (upper vs 
lower gastrointestinal), suspected variceal bleeding and 
comorbid liver disease compared with other or unknown 
causes of bleeding, and by clinical Rockall score. We 
modelled an interaction between the treatment effect 
and time to treatment with time to treatment as a 
continuous variable. We did post­hoc subgroup analyses 
to examine the effects of tranexamic acid on the primary 
outcome stratified by World Bank country income level 
(high vs low and middle income), anticoagulant use, and 
systolic blood pressure.
This trial was registered with Current Controlled Trials, 
ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.
Role of the funding source 
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding authors had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
We enrolled the first patient on July 4, 2013, and the last on 
June 21, 2019. We stopped recruiting when the planned 
sample size was reached. When the decision to refine the 
primary outcome was made in Nov 21, 2018, we had 
recruited 10 190 patients. This decision was made blind to 
the accumulating trial data. 12 009 patients were enrolled 
and randomly assigned to receive either tranexamic acid 
(n=5994, 49·9%) or matching placebo (n=6015, 50·1%), 
of whom 11 952 (99·5%) received the first dose of the 
allocated treatment (figure 1). 29 patients (11 in the 
tranexamic acid group and 18 in the placebo group) 
withdrew consent after randomisation, but of those, 
12 (five in the tranexamic acid group and seven in the 
placebo group) agreed to provide outcome data or had 
outcome data collected as part of adverse event reporting. 
We obtained primary outcome data for all but three 
patients in the tranexamic acid group. There were 
14 protocol violations (seven in the tranexamic acid group 
and seven in the placebo group), 11 patients did not meet 
the inclusion criteria (ten received tranexamic acid before 
randomisation [six in the tranexamic acid group and four 
in the placebo group], one in the placebo group was 
younger than 16 years), and there were three consent 
protocol violations (one in the tranexamic acid group and 
two in the placebo group). A total of 28 patients were 
unmasked to treatment (17 patients because the hospital 
team wanted to admin ister tranexamic acid, six because of 
adverse events, three because of clinical concerns, and 
two as part of post­mortem investigations [13 in the 
tranexamic acid group and 15 in the placebo group]). 
52 patients received neither dose of the allocated trial 
treatment (29 patients in the tranexamic acid group and 
23 patients in the placebo group).
223 patients received antifibrinolytic drugs as part of 
their clinical care, outside of the trial protocol (105 patients 
in the tranexamic acid group and 118 patients in the 
placebo group).
Baseline characteristics were similar between groups 
(table 1). Figure 2 shows the number of deaths and cause 
of death by days since randomisation. There were 
1112 deaths. The median time to death was 55 h after 
randomisation (IQR 18·2–161·8).
Figure 3: Effect of tranexamic acid on death due to bleeding within 5 days
Analysis stratified by time since bleeding onset, suspected bleed location, suspected variceal bleeding or comorbid 
liver disease, and Rockall score.
Time since onset
≤3 h
>3 h
p=0·53
Bleed location
Upper
Lower
p=0·34
Variceal or liver
Yes
No or unknown
p=0·94
Rockall score
1–2
3–4
5–7
p=0·32
Total
 1·10
 0·96
 0·97
 1·61
 1·01
 0·99
 0·64
 0·98
 1·06
 0·99
Risk ratio
(0·75–1·61)
(0·78–1·18)
(0·81–1·17)
(0·59–4·40)
(0·81–1·24)
(0·70–1·40)
(0·35–1·18)
(0·70–1·38)
(0·84–1·33)
(0·82–1·18)
95% CI
 48 (4·9%)
 178 (3·6%)
 220 (4·1%)
 6 (0·9%)
 165 (5·5%)
 61 (2·1%)
 26 (1·9%)
 65 (2·8%)
 135 (5·9%)
 226 (3·8%)
Placebo 
(n=5981)
 52 (5·4%)
 170 (3·4%)
 212 (4·0%)
 10 (1·5%)
 160 (5·5%)
 62 (2·0%)
 17 (1·2%)
 63 (2·7%)
 142 (6·3%)
 222 (3·7%)
Tranexamic acid
(n=5956)
0·35 1·0 1·6
Tranexamic acid 
(n=5956)
Placebo 
(n=5981)
Risk ratio 
(95% CI)
Bleeding 253 (4·2%) 262 (4·4%) 0·97 (0·82–1·15)
Thromboembolic event 26 (0·4%) 17 (0·3%) 1·54 (0·83–2·83)
Organ failure 109 (1·8%) 114 (1·9%) 0·96 (0·74–1·25)
Pneumonia 57 (1·0%) 42 (0·7%) 1·36 (0·92–2·03)
Sepsis 33 (0·6%) 49 (0·8%) 0·68 (0·44–1·05)
Malignancy 65 (1·1%) 40 (0·7%) 1·63 (1·10–2·42)
Other 21 (0·4%) 24 (0·4%) 0·88 (0·49–1·58)
All cause 564 (9·5%) 548 (9·2%) 1·03 (0·92–1·16)
Data are n (%) and risk ratio (95% CI). Death in hospital during follow-up.
Table 3: Effect of tranexamic acid on all-cause death
Articles
1932 www.thelancet.com   Vol 395   June 20, 2020
Death due to bleeding within 5 days of randomisation 
(table 2) occurred in 222 (3·7%) of 5956 patients in the 
tranexamic acid group and in 226 (3·8%) of 5981 patients 
in the placebo group (RR 0·99, 95% CI 0·82–1·18). 
Similar results were obtained after adjusting for baseline 
covariates (0·98, 0·82–1·17) and in a per­protocol analysis 
(0·94, 0·71–1·23). When the 223 patients who received 
open­label antifibrinolytics were removed from the 
analysis, the results were similar (0·97, 0·81–1·17). We 
examined the effect of tranexamic acid on death due to 
bleeding within 5 days of randomisation in prespecified 
subgroup analyses stratified by time to treatment 
(heterogeneity p=0·53), location of bleeding (p=0·34), 
cause of bleeding (p=0·94), and clinical Rockall score 
(p=0·32) but recorded no evidence of heterogeneity for 
these factors (figure 3). When time since bleeding onset 
was modelled as a continuous variable there was no 
evidence of an interaction (heterogeneity p=0·53).
We examined the effect of tranexamic acid on death 
due to bleeding within 5 days of randomisation stratified 
by World Bank country income level (high­income vs 
low­income and middle­income), anticoagulant use 
and systolic blood pressure. These exploratory analyses 
were not prespecified. The relative risks did not appear 
to vary by country income, anticoagulant use, or systolic 
blood pressure (appendix p 6).
Death due to bleeding within 24 h of randomisation 
occurred in 124 (2·1%) patients in the tranexamic 
acid group and 120 (2·0%) patients in the placebo 
group (RR 1·04, 95% CI 0·81–1·33). Death due to 
bleeding within 28 days of randomisation occurred in 
253 (4·2%) patients in the tranexamic acid group 
and 262 (4·4%) patients in the placebo group (0·97, 
0·82–1·15). Death from all­causes within 28 days of 
randomisation occurred in 564 patients (9·5%) in the 
tranexamic acid group and in 548 patients (9·2%) in the 
placebo group (1·03, 0·92–1·16; table 3). The proportion 
of patients with rebleeding was similar in both groups 
at 24 h, 5 days, and 28 days after randomisation (table 3). 
The proportion of patients who had surgery, radiological 
intervention, and blood product transfusion was also 
similar in both groups (table 4).
The risk of fatal or non­fatal thromboembolic events 
and arterial thromboembolic events (myocardial infarc­
tion or stroke) was similar in the tranexamic acid 
group and the placebo group (table 5). The risk of 
venous thromboembolic events (deep vein thrombosis 
or pulmonary embolus) was higher in the tranexamic 
group than in the placebo group (table 5) and similar 
risk was observed after excluding patients who did not 
receive the maintenance dose (42 events with tranexamic 
acid vs 20 with placebo); RR 2·11, 95% CI 1·24–3·59). In 
an exploratory subgroup analysis, the risk of venous 
thromboembolic events was higher in patients with 
suspected variceal bleeding or liver disease (14 vs two 
events; 7·26, 1·65–31·90) than in patients with other 
causes of bleeding (34 vs 24 events; 1·38, 0·82–2·32; 
p=0·035 for heterogeneity). The risk of renal, hepatic, 
and respiratory failure, cardiac events, sepsis, and 
pneumonia was similar in tranexamic acid and placebo 
treated patients (table 5). Seizures occurred in 38 patients 
on tranexamic acid and 22 on placebo (0·6% vs 0·4%; 
1·73, 1·03–2·93; table 5), and after excluding patients 
who did not receive the maintenance dose the 
Tranexamic acid Placebo Outcomes
Interventions
Diagnostic endoscopy 4781/5953 (80·3%) 4729/5978 (79·1%) 1·02 (1·00 to 1·03)
Therapeutic endoscopy 2542/5952 (42·7%) 2658/5978 (44.5%) 0·96 (0·92 to 1·00)
Diagnostic radiological procedure 1704/5953 (28·6%) 1744/5978 (29·2%) 0·98 (0·93 to 1·04)
Therapeutic radiological procedure 74/5953 (1·2%) 89/5978(1·5%) 0·83 (0·61 to 1·13)
Surgical intervention 146/5953 (2·5%) 158/5978 (2·6%) 0·93 (0·74 to 1·16)
Any surgical, endoscopic, 
or radiological intervention
5216/5956 (87·6%) 5236/5981 (87·5%) 1·00 (0·99 to 1·01)
Any transfusion 4076/5951 (68·5%) 4129/5978 (69·1%) 0·99 (0·97 to 1·02)
Whole blood or red cells 3984/4076 (97·7%) 4018/4129 (97·3%) 1·00 (1·00 to 1·01)
Frozen plasma 910/4076 (22·3%) 993/4129 (24·0%) 0·93 (0·86 to 1·00)
Any platelets 219/4076 (5·4%) 255/4129 (6·2%) 0·87 (0·73 to 1·04)
Blood product transfusions
Units of whole blood or red cells 2·8 (2·4) 2·9 (2·7) –0·06 (0·05 to –0·18)
Units of frozen plasma 0·9 (2·4) 1·0 (2·6) –0·05 (–0·01 to –0·23)
Units of any platelets 0·2 (0·9) 0·2 (1·0) –0·02 (0·02 to –0·06)
Data for interventions are n/N (%) and risk ratio (95% CI); data for blood product transfusions are mean (SD) and 
difference in means (95% CI).
Table 4: Effect of tranexamic acid on the need for surgical, endoscopic, and radiological interventions or 
blood product transfusion
Tranexamic acid Placebo Outcomes
 Complications
Any thromboembolic event 86/5952 (1·4%) 72/5977 (1·2%) 1·20 (0·88 to 1·64)
Venous events (deep vein 
thrombosis, pulmonary embolism)
48/5952 (0·8%) 26/5977 (0·4%) 1·85 (1·15 to 2·98)
Deep vein thrombosis 23/5952 (0·4%) 12/5977 (0·2%) 1·92 (0·96 to 3·86)
Pulmonary embolism 28/5952 (0·5%) 16/5977 (0·3%) 1·76 (0·95 to 3·24)
Arterial events (myocardial 
infarction, stroke)
42/5952 (0·7%) 46/5977 (0·8%) 0·92 (0·60 to 1·39)
Myocardial infarction 24/5952 (0·4%) 28/5977 (0·5%) 0·86 (0·50 to 1·48)
Stroke 19/5952 (0·3%) 18/5977 (0·3%) 1·06 (0·56 to 2·02)
Renal failure 142/5951 (2·4%) 157/5978 (2·6%) 0·91 (0·73 to 1·14)
Liver failure 196/5952 (3·3%) 184/5977 (3·1%) 1·07 (0·88 to 1·30)
Respiratory failure 105/5952 (1·8%) 131/5978 (2·2%) 0·81 (0·62 to 1·04)
Cardiac event 100/5952 (1·7%) 89/5977 (1·5%) 1·13 (0·85 to 1·50)
Sepsis 210/5952 (3·5%) 216/5977 (3·6%) 0·98 (0·81 to 1·18)
Pneumonia 193/5952 (3·2%) 174/5978 (2·9%) 1·11 (0·91 to 1·36)
Seizure 38/5952 (0·6%) 22/5977 (0·4%) 1·73 (1·03 to 2·93)
Self-care capacity
Days in ICU 0·4 (1·8) 0·4 (2·0) –0·06 (0·01 to –0·13)
Katz score 5·5 (1·5) 5·5 (1·4) –0·03 (0·02 to –0·09)
Data for complications are n/N (%) and risk ratio (95% CI); data for self-care capacity are mean (SD) and difference in 
means (95% CI). Thromboembolic events and complications are not mutually exclusive. ICU=intensive care unit.
Table 5: Complications and self-care capacity in study groups
See Online for appendix
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corresponding numbers were 33 versus 17 events (1·95, 
1·09–3·50).
The mean number of days spent in intensive care was 
similar in both groups (table 5). The mean score on the 
Katz Index of Independence in Activities of Daily Living 
was also similar in both groups (table 5).
Discussion
In this trial, tranexamic acid did not reduce death from 
gastrointestinal bleeding but was associated with an 
increased risk of venous thromboembolic events and 
seizures. The proportion of patients with rebleeding was 
similar in the tranexamic acid and placebo groups.
The randomisation method ensured that participating 
clinicians had no foreknowledge of the treatment allo­
cation and placebo control ensured outcome assessment 
was blind to treatment group. The inclusion criteria 
were clinical, reflecting the full range of gastrointestinal 
bleeding presentations that doctors face in day­to­day 
practice. Baseline prognostic factors were well balanced 
and almost all randomly assigned patients were followed 
up. The primary outcome was death due to bleeding 
within 5 days of randomisation. Our scientific reasons 
for pre­specifying death due to bleeding as the primary 
outcome in the statistical analysis plan are presented in 
detail elsewhere.12 Although some misclassification of 
cause of death is possible, the assessment was masked 
to the treatment group. However, because there was no 
evidence of a treatment effect for the prespecified 
primary endpoint (death due to bleeding at 5 days) or 
for death from any cause at 28 days, the choice of 
endpoint does not influence the interpretation of the 
results. Misclassification might also have affected our 
subgroup analyses because at the time of recruitment 
the site and cause of bleeding cannot be known with 
certainty. Our use of the pre­endoscopy Rockall score 
might have misclassified baseline risk.14 To minimise 
the risk of false positives, we used strict criteria to 
diagnose thromboembolic events, including a positive 
result on imaging (eg, ultrasound) or at post­mortem 
examination. Although using this criteria might have 
led to some under reporting, because the diagnostic 
tests have high specificity, the relative risk estimates 
should be unbiased. Although some patients received 
anti fibrinolytics outside of the protocol, the treatment 
effect was the same when these patients were excluded. 
Although this is one of the largest randomised trials 
in gastrointestinal bleeding, we cannot rule out a 
modest increase or decrease in death due to bleeding 
with tranexamic acid. That said, we can rule out the 
large mortality reduction suggested by the Cochrane 
systematic review and meta­analysis of previous small 
trials.9
Administration of tranexamic acid within 3 h of 
bleeding onset reduces death due to bleeding in trauma 
and post­partum haemorrhage without increasing 
the risk of thromboembolic events. In these bleeding 
scenarios, the timing of onset is easy to determine, most 
patients present early, and there are well documented 
changes in fibrinolysis that provide a biological rationale 
for tranexamic acid treatment.15,16 However, in gastro­
intestinal bleeding it is difficult to determine the time of 
bleeding onset, presentation is often delayed (over 
80% of patients presented more than 3 h after bleeding 
onset), and the contribution of increased fibrinolysis to 
bleeding is less clear.
Almost half of the patients included in our trial had 
suspected variceal bleeding due to liver disease and 
because these patients had a greater risk of death, they 
accounted for nearly three­quarters of deaths. Recent 
research shows that acutely ill patients with cirrhosis 
have a mixed fibrinolytic phenotype.17 Some have 
increased fibrinolysis, but others have profound hypo­
fibrinolysis. The prevalence of hypofibrinolysis appears 
to be greatest in the most critically ill patients. Using the 
same clot lysis assay, reduced fibrinolysis has been 
shown to be associated with a small increased risk of 
venous thrombosis.18 In our trial, the increased risk of 
venous thromboembolic events with tranexamic acid 
appeared to be more marked in patients with liver 
disease, although this was an explo ratory subgroup 
analysis and there was no strong evidence for hetero­
geneity. Nevertheless, reduced fibrinolysis in patients 
with liver disease might explain the absence of reduction 
in bleeding deaths with tranexamic acid and the 
increased risk of venous thromboembolic events.
The dose of tranexamic acid used in this trial was 
higher and the duration of treatment was longer (4 g over 
24 h) than in randomised trials of tranexamic acid in 
trauma (2 g over 8 h) or post­partum haemorrhage (1 g 
bolus with a repeat 1 g dose if bleeding continued), which 
did not record any increase in adverse events with 
tranexamic acid. Patients with gastrointestinal bleeding 
often rebleed after initial haemostasis, particularly 
within the first 24 h. Because tranexamic acid has a short 
half­life, we used a longer treatment duration to cover 
this high­risk period. Furthermore, previous trials in 
gastrointestinal bleeding that appeared to show a large 
mortality reduction with tranexamic acid used a high 
dose and a longer duration of treatment than trials in 
trauma and post­partum haemorrhage.9 The longer 
duration of tranexamic acid treatment in this trial might 
explain the increased risk of venous thromboembolic 
events and the higher dose could possibly explain the 
increased risk of seizures.19
In summary, we found no evidence that tranexamic 
acid decreases the risk of death in patients with gastro­
intestinal bleeding. Our results caution against a uniform 
approach to the management of patients with major 
haemorrhage and highlight the need for randomised 
trials targeted at specific pathophysiological processes. 
Because gastrointestinal bleeding is a licensed indi cation 
for tranexamic acid, our results could have regulatory 
implications. Although this trial can rule out the large 
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mortality reduction suggested by the meta­analysis of 
previous small trials, it cannot rule out more modest 
treatment effects. Because tranexamic acid reduces 
bleeding deaths in patients with traumatic and post­
partum haemorrhage, individual patient data meta­
analyses should assess the strength of the evidence that 
the effectiveness and safety of tranexamic acid varies by 
the site and cause of bleeding.
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